Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001227-39
    Sponsor's Protocol Code Number:779322
    National Competent Authority:Norway - NOMA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-11-06
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNorway - NOMA
    A.2EudraCT number2018-001227-39
    A.3Full title of the trial
    A randomized controlled clinical trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in comparison to autologous bone block grafting.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate if the use of the patients own stem cells in combination with a biomaterial is as good as the standard treatment, bone transplantation.
    A.3.2Name or abbreviated title of the trial where available
    Maxibone
    A.4.1Sponsor's protocol code number779322
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity of Bergen, Faculty of Medicin, Department of Clinical Dentistry
    B.1.3.4CountryNorway
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUniversity of Bergen, Faculty of Medicin, Department of Clinical Dentistry
    B.4.2CountryNorway
    B.4.1Name of organisation providing supportInserm UMR 1238, PHY-OS Faculty of Medicine, University of Nantes
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportUniversidad Complutense de Madrid
    B.4.2CountrySpain
    B.4.1Name of organisation providing supportSyddansk Universitet SDU
    B.4.2CountryDenmark
    B.4.1Name of organisation providing supportHaukeland University Hospital, Clinical trial unit
    B.4.2CountryNorway
    B.4.1Name of organisation providing supportUniversitat Internacional De Catalunya Fundacio Privada
    B.4.2CountrySpain
    B.4.1Name of organisation providing supportAssistance Publique - Hôpitaux De Paris
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportInstitute for Transfusion Medicine and Immunogenetic Ulm, University Hospital Ulm (IKT Ulm) and German Red Cross Blood T
    B.4.2CountryGermany
    B.4.1Name of organisation providing supportUniversitaet Ulm
    B.4.2CountryGermany
    B.4.1Name of organisation providing supportBiomatlante
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportStraumann
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversity of Bergen, Faculty of Medicin, Department of Clinical Dentistry
    B.5.2Functional name of contact pointCecilie Gjerde
    B.5.3 Address:
    B.5.3.1Street AddressAarstadveien 19
    B.5.3.2Town/ cityBergen
    B.5.3.3Post code5009
    B.5.3.4CountryNorway
    B.5.4Telephone number+4755586441
    B.5.6E-mailcecilie.gjerde@uib.no
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMesenchymal stem cells and microporous Bi-phasic calcium phosphate (MBCP+)
    D.3.2Product code Maxibone-1
    D.3.4Pharmaceutical form Granules
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPDental use
    Implantation
    Periosseous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product Yes
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Yes
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients in need of dental implant(s) in the upper and lower jaws with presence of bone defects with loss in vertical height and < than 4 mm in lateral width
    E.1.1.1Medical condition in easily understood language
    Lack of bone width (and sometimes hight), so that it is not possible to place dental implants.
    E.1.1.2Therapeutic area Diseases [C] - Mouth and tooth diseases [C07]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Principal objective: To compare linear changes in bone width between
    the tested interventions aimed for vertical and lateral bone
    augmentation; test (combination of autologous culture expanded
    mesenchymal stem cells and biomaterials) and control groups
    (autologous bone block graft from ramus fixed with osteosynthesis
    screws)
    E.2.2Secondary objectives of the trial
    (1) To evaluate efficacy of treatment and formation of new bone by:
    assessing the possibility to insert an implant 5 months after the grafting procedure (3D CBCT)
    Measuring clinical changes in alveolar bone width.
    evaluating the collected core biopsies using μCT, SRμCT and histology.
    evaluting outcomes after implant placement
    (2) To evaluate the safety of the interventions by:
    assessing adverse effects (AEs) and soft tissue healing at 2 and 4 weeks and 5 months
    assessing the morbidity associated with both procedures by measuring the usage of postoperative anti-inflammatory medication and degree of reported pain using a VAS scale
    assessing fate of the transplanted MSCs by liquid biopsy (blood samples and plasma/sera at screening and 2 weeks after bone augmentation surgery)
    (3) To assess patient’s satisfaction with surgical intervention and prosthetic outcome by patient reported outcomes (PROMs). Impact of treatment on the patient’s overall quality of life (QoL) will be assessed
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    •Written informed consent
     Patient should be able to understand and complete the informed consent
     Age 18 years or older
     Insufficient bone ridge width (≤ than 4 mm) and or height at the recipient site for
    titanium dental implant placement
     Patient should be eligible for bone marrow harvest and bone transplant
     Healthy oral mucosa, at least 2 mm keratinized mucosa
     Female candidates of child bearing potential (WOCBP) -as defined by CTFG 2- must be
    referred to their physician for a pregnancy test 1,2 before inclusion in the study. In
    case of a negative preganancy test their physician will be asked to prescribe one of
    the highly effective birth control methods recommended by CTFG 2 which includes:
    1. Combined estrogen and progestogen containing contraceptives that are
    associated with inhibition of ovulation (oral, intravaginal or transdermal).
    2. Progestogen-only hormonal contraceptives associated with inhibition of
    ovulation (oral, injectable or implantable).
    3. Intrauterine devices.
    4. Intrauterine hormone-releasing system.
    5. Bilateral tubal occlusion.
     The WOCBP candidates will only be included in the study if the pregnency tests are
    negative. These patients must continue using the contraceptives until the placement
    of dental implants (5 months after bone augmentation procedure considering that
    pregnancy is not considered as a contraindication for normal dental implant).
     Female candidates that have entered menopause for less than 12 months must also
    be referred to confirm post-menopausal state by testing the level of follicle
    stimulating hormone (FSH).
    E.4Principal exclusion criteria
    General contraindications for dental and/or surgical treatments
    · Contraindications for both bone marrow harvesting and bone grafts:
    o General:
    § Patients with severe bone marrow diseases such as leukemias, lymphomas, and myelodysplastic syndromes.
    § Patients with severe respiratory disease, chronic respiratory failure, medical history of generalized allergic manifestation.
    § Patients with a history of severe osteoporosis.
    § Patients suffering from any serious coagulation disorders that could require substitution therapy.
    § Patients receiving anticouagulant treatment should be adjusted in collaboration with the treating physician.
    § Patients with total hip prothesis
    o Local:
    § Patients with active infection at the harvest site
    § Patients with previous pathology or trauma at the harvest site
    · History of any malignant diseases
    · Concurrent or previous radiotherapy of head and neck region
    · History of contagious diseases (HIV, HTLV and/or syphilis seropositivity, hepatitis B or C infection)
    · Uncontrolled diabetes mellitis, e.g. patients with diabetes not regulated with medications or diet. This will be verified based on patient`s history and concurrent HbA1c levels (HbA1c > 53 mmol/mol).
    · Inflammatory and autoimmune disease of the oral cavity.
    · Concurrent or previous immunosuppressant, bisphosphonate or high dose corticosteroid therapy.
    · Patients with a history of drug addiction.
    · Patients with known hypersensitivity against paracetamol, codein or xylocaine.
    · Thin keratinized mucosa (< 1mm)
    · Current smokers and those who have quitted smoking in the last 4 weeks (there is evidence that nicotine and cotinine levels disappear after 4 weeks of non-smoking).
    · Pregnant or lactating women.
    · Participation in an investigational device, drug or biologics study within the last 24 weeks prior to the study start
    E.5 End points
    E.5.1Primary end point(s)

    Principal assessment is linear change in bone width 2 mm below alveolar crest measured by
    means of CBCT images from baseline to 5 months after the regenerative surgery, immediately
    prior to implant placement.
    E.5.1.1Timepoint(s) of evaluation of this end point
    After 5,5 +- 14 days
    E.5.2Secondary end point(s)
    PROMS, implant stability, QoL, AE assessment
    E.5.2.1Timepoint(s) of evaluation of this end point
    At 21 months.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Bone transplantation
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA6
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 50
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 110
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard operating procedures for these patients
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-11-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-12-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-08-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:25:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA